

## Lupin launches Mycophenolate Mofetil Capsules USP

**Mumbai, Baltimore, October 4, 2019:** Pharma major Lupin Limited (Lupin) announced the launch of Mycophenolate Mofetil Capsules USP, 250 mg. Lupin's alliance partner Concord Biotech Limited (Concord) had received an approval from the United States Food and Drug Administration (U.S. FDA) earlier.

Mycophenolate Mofetil Capsules USP, 250 mg, is the generic version of Roche's CellCept®. Mycophenolate Mofetil Capsules are an antimetabolite immunosuppressant indicated for the prophylaxis of organ rejection in recipients of allogeneic kidney, heart or liver transplants, and should be used in combination with other immunosuppressants.

Mycophenolate Mofetil Capsules USP, 250 mg, had annual sales of approximately USD 53 million in the U.S. (IQVIA MAT August 2019).

### About Lupin Limited

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.

Lupin is the 8<sup>th</sup> largest generics pharmaceutical company by revenues (31<sup>st</sup> Mar 2019, Bloomberg LTM) respectively. The Company is the 3<sup>rd</sup> largest pharmaceutical player in the US by prescriptions (IQVIA MAT Jun 2019); 3<sup>rd</sup> largest Indian pharmaceutical company by global revenues (31<sup>st</sup> Mar 2019, Bloomberg LTM); 5<sup>th</sup> largest generic pharmaceutical player in Japan and 6<sup>th</sup> largest company in the Indian Pharmaceutical Market (IQVIA MAT Jun 2019).

For the financial year ended 31<sup>st</sup> March 2019, Lupin's Consolidated sales and Net profits were at Rs. 163,694 million (USD 2.34 billion) and Rs. 9,466 million (USD 136 million) respectively. Please visit <http://www.lupin.com> for more information. You could also follow us on Twitter – [www.twitter.com/lupinglobal/](http://www.twitter.com/lupinglobal/)

CIN: L24100MH1983PLC029442 Registered Office: Lupin Ltd, 3rd Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai 400 055.

### For further information or queries please contact-

Arvind Bothra

Head – Investor Relations and M&A / Corporate Communications

Ph: +91-22 6640 8237

Email: [arvindbothra@lupin.com](mailto:arvindbothra@lupin.com)

### \*Safe Harbor Statement

CellCept® is a registered trademark of Roche Group member company